Liver function may change how radiprodil works – new study aims to find out

NCT ID NCT07457229

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing how the drug radiprodil behaves in people with mild, moderate, or severe liver problems compared to healthy adults. About 40 participants will receive a single dose and be monitored for about a week. The goal is to see if liver impairment affects drug levels in the body, which will help guide safe dosing in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Radiprodil (oral suspension)
What this could lead to
If successful, this study could help doctors determine the right dose of radiprodil for people with liver problems, making future treatments safer.
What could go wrong
This is a very early Phase 1 study with only 40 people. It is designed to measure drug levels, not to treat any disease, so there is no direct benefit to participants. Liver impairment may affect results unpredictably.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Epic Medical Research

    RECRUITING

    DeSoto, Texas, 75115, United States

  • Texas Liver Institute

    RECRUITING

    San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.